Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.8% and a 52.68% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis ...

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF104.00. The company’s shares cl ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...

All three major U.S. stock market indices suffered a fall of more than 1% on June 13 following the exchange of missile ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Novartis has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal ...

Novartis Fabhalta shows statistically significant and clinically meaningful improvements in haemoglobin in new population of patients with PNH: Basel Friday, June 13, 2025, 09:00 ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.